Lucksiri Aroonrut, Scott Meri K, Mueller Bruce A, Hamburger Richard J, Sowinski Kevin M
Department of Pharmacy Practice, School of Pharmacy and Pharmacal Sciences, Purdue University, Indianapolis 46202, USA.
Nephrol Dial Transplant. 2002 Sep;17(9):1649-54. doi: 10.1093/ndt/17.9.1649.
Vancomycin is often administered during the last hour of haemodialysis because it was not removed significantly by older hemodialyzers. However, newer higher permeability hemodialyzers remove vancomycin, although the amount removed varies considerably between dialyzers. The purpose of this study was to determine the apparent amount of vancomycin removed during the last hour of haemodialysis with a CAHP-210 hemodialyzer.
Eight subjects with end-stage renal disease (ESRD) received i.v. vancomycin 15 mg/kg after their regular haemodialysis session ended. Serum samples for the determination of vancomycin concentrations were obtained serially for 44 h. After a 3-week washout, the study was repeated with the vancomycin infused during the last hour of their regular haemodialysis session using a CAHP-210 hemodialyzer. Vancomycin concentrations were determined by the Enzyme Multiplied Immunoassay Technique. Differential equations describing a two-compartment open infusion model were fitted to the serum concentration vs time data and pharmacokinetic parameters and apparent vancomycin removal was estimated.
The median age and weight of the subjects were 52 years (range 37-71) and 75.6 kg (range 37.6-89.8), respectively. The apparent vancomycin intra-dialytic removal was 0.24 (range -0.07-0.35), which was statistically significantly different from zero.
Vancomycin administered during the last hour of CAHP-210 dialysis results in 24% less vancomycin exposure than when administered post-haemodialysis. This intra-dialytic drug loss should be accounted for when dosing vancomycin in this manner.
万古霉素通常在血液透析的最后一小时给药,因为在老式血液透析器中其清除率不高。然而,新型的高通透性血液透析器能够清除万古霉素,尽管不同透析器的清除量差异很大。本研究的目的是确定使用CAHP - 210血液透析器在血液透析最后一小时内万古霉素的表观清除量。
8名终末期肾病(ESRD)患者在常规血液透析疗程结束后静脉注射15mg/kg万古霉素。连续44小时采集血清样本以测定万古霉素浓度。经过3周的洗脱期后,重复该研究,在使用CAHP - 210血液透析器的常规血液透析疗程的最后一小时内输注万古霉素。采用酶联免疫分析技术测定万古霉素浓度。将描述二室开放输注模型的微分方程拟合到血清浓度与时间的数据,并估算药代动力学参数和万古霉素的表观清除量。
受试者的中位年龄和体重分别为52岁(范围37 - 71岁)和75.6kg(范围37.6 - 89.8kg)。透析期间万古霉素的表观清除量为0.24(范围 - 0.07 - 0.35),与零有统计学显著差异。
在CAHP - 210透析的最后一小时给予万古霉素,与透析后给药相比,万古霉素的暴露量减少24%。以这种方式给万古霉素给药时应考虑透析期间的药物损失。